太平洋特异性CREBRF rs373863828等位基因对肥胖毛利与太平洋岛裔女性妊娠期糖尿病的保护作用
在112名肥胖毛利与太平洋岛裔孕妇的前瞻性队列中,携带CREBRF rs373863828 A等位基因者占28%,31%发生妊娠期糖尿病;每携带一个A等位基因,妊娠期糖尿病风险约降低五倍(OR 0.19,95%CI 0.05-0.69,p=0.01),校正年龄、BMI和糖尿病家族史后仍显著(校正OR 0.13,95%CI 0.03-0.53,p=0.004)。
要点
- 肥胖毛利与太平洋岛裔孕妇中,携带CREBRF rs373863828 A等位基因者妊娠期糖尿病风险约降低五倍。
- 携带者与非携带者BMI无差异,A等位基因与妊娠期糖尿病风险降低独立于年龄、BMI和糖尿病家族史。
- 携带A等位基因者妊娠期糖尿病发生率为10%,非携带者为40%,A/A基因型者无妊娠期糖尿病发生。
核心结论
- CREBRF rs373863828 A等位基因与肥胖毛利与太平洋岛裔女性妊娠期糖尿病风险降低相关,可能改善妊娠期糖尿病风险预测。
研究设计与样本
- 前瞻性队列研究,嵌套于一项针对肥胖孕妇的营养干预研究,纳入112名毛利与太平洋岛裔孕妇,于孕12-17周入组。
- 妊娠期糖尿病依据国际糖尿病与妊娠研究组协会标准,于孕24-28周行75克口服葡萄糖耐量试验诊断。
- 采用实时PCR定制CREBRF rs373863828探针组进行基因分型,按族群分别用逻辑回归分析关联,效应估计值通过荟萃分析合并。
主要发现
- 112名肥胖毛利与太平洋岛裔孕妇中,31名(28%)携带CREBRF rs373863828 A等位基因(A/G或A/A),35名(31%)发生妊娠期糖尿病。
- 携带CREBRF rs373863828 A等位基因者与非携带者(G/G)相比BMI无差异。
- 每携带一个CREBRF rs373863828 A等位基因,妊娠期糖尿病可能性降低五倍(OR 0.19,95%CI 0.05-0.69,p=0.01)。
- 校正年龄、BMI和糖尿病家族史后,关联仍显著(校正OR 0.13,95%CI 0.03-0.53,p=0.004)。
- 携带与不携带CREBRF rs373863828 A等位基因的女性中,妊娠期糖尿病诊断率分别为10%和40%,A/A基因型者无一发生妊娠期糖尿病。
关键数值与推荐
- 妊娠期糖尿病诊断采用国际糖尿病与妊娠研究组协会标准,于孕24-28周行75克口服葡萄糖耐量试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The CREBRF rs373863828 minor (A) allele is associated with increased BMI but reduced prevalence of type 2 diabetes in Māori and Pacific people. Given the shared aetiology of type 2 diabetes and gestational diabetes mellitus (GDM), we tested for an association between the CREBRF rs373863828 variant and GDM. METHODS: We conducted a prospective cohort study of Māori and Pacific women nested within a nutritional intervention study for pregnant women with obesity. Women were enrolled at 12-17 weeks' gestation and underwent anthropometry and collection of buffy coats for later genetic testing. GDM was diagnosed by 75 g OGTT at 24-28 weeks' gestation using the International Association of Diabetes and Pregnancy Study Groups criteria. Genotyping was performed by real-time PCR with a custom CREBRF rs373863828 probe-set. The association between CREBRF rs373863828 and GDM was analysed separately by ethnic group using logistic regression, with effect estimates combined in a meta-analysis. RESULTS: Of 112 Māori and Pacific pregnant women with obesity, 31 (28%) carried the CREBRF rs373863828 A allele (A/G or A/A) and 35 (31%) developed GDM. Women who carried the CREBRF rs373863828 A allele did not differ in BMI when compared with non-carriers (G/G). There was a fivefold reduction in the likelihood of GDM per CREBRF rs373863828 A allele (OR 0.19 [95% CI 0.05, 0.69], p = 0.01), independent of age, BMI and family history of diabetes (adjusted OR 0.13 [95% CI 0.03, 0.53], p = 0.004). GDM was diagnosed in 10% and 40% of women with and without the CREBRF rs373863828 A allele, respectively (no woman with the A/A genotype developed GDM). CONCLUSIONS/INTERPRETATION: The CREBRF rs373863828 (A) allele is associated with reduced likelihood of GDM in Māori and Pacific women with obesity and may improve GDM risk prediction. Graphical abstract.
引用
- Krishnan M, Murphy R, Okesene-Gafa KAM, et al. The Pacific-specific CREBRF rs373863828 allele protects against gestational diabetes mellitus in Māori and Pacific women with obesity. Diabetologia. 2020. PMID: 32654027. doi:10.1007/s00125-020-05202-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。